This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LEXXW Lexaria Bioscience (LEXXW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Lexaria Bioscience Stock (NASDAQ:LEXXW) Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$0.0009▼$0.004550-Day Range$0.00▼$0.0352-Week Range$0.00▼$0.80Volume283,190 shsAverage Volume55,749 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lexaria Bioscience Corp. is a pharmaceutical company specializing in the development of novel drug delivery platforms for orally administered, lipid-soluble molecules. The company’s core technology, DehydraTECH®, is designed to enhance the absorption, onset and bioavailability of compounds such as cannabinoids, nicotine and certain pharmaceutical actives. By embedding these compounds into food and beverage products or nutraceuticals, Lexaria aims to offer a more efficient alternative to traditional delivery methods. Established in 2012 and headquartered in Kelowna, British Columbia, Lexaria has conducted preclinical and clinical studies to validate its DehydraTECH® platform. The technology has been applied across multiple product categories, including prescription drug candidates, over-the-counter consumer goods and wellness supplements. Lexaria pursues collaboration and licensing agreements with industry partners to integrate its delivery system into a range of formulations. In its pharmaceutical pipeline, Lexaria has advanced a variety of cannabinoid-based drug candidates targeting cardiovascular health, pain management and inflammation. The company also explores applications for nicotine reduction products and the enhanced delivery of vitamins and antiviral agents. Through ongoing research partnerships with academic institutions and contract research organizations, Lexaria continues to expand the evidence base supporting DehydraTECH®’s performance. Lexaria’s leadership team is led by President and Chief Executive Officer Mr. Greg Gzerowicz, alongside founder and Chairman Mr. Chris Bunka. As a publicly traded entity on the NASDAQ under the symbol LEXXW, the company operates primarily in North America but actively pursues regulatory approvals and commercial collaborations in Europe, Latin America and the Asia-Pacific region. Lexaria remains focused on unlocking the full potential of lipid-soluble therapeutics through innovative drug delivery solutions.AI Generated. May Contain Errors. Read More Receive LEXXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEXXW Stock News HeadlinesLexaria Bioscience Earnings Analysis: Q1 RecapJanuary 10, 2025 | benzinga.comLexaria Bioscience finalizes clinical study agreementDecember 20, 2024 | uk.investing.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 25 at 1:00 AM | Banyan Hill Publishing (Ad)LEXX: Phase I Start ImminentDecember 5, 2024 | msn.comLexaria Bioscience Corp.: Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as ScheduledNovember 27, 2024 | finanznachrichten.deLexaria Bioscience’s DehydraTECH Outshines in Diabetes StudyNovember 21, 2024 | markets.businessinsider.comLexaria Bioscience Corp.: Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesOctober 17, 2024 | finanznachrichten.deLexaria Bioscience (NASDAQ:LEXX) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LEXXW CIK1348362 Weblexariaenergy.com Phone250-765-6424FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$705.92 thousand Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:LEXXW) was last updated on 1/13/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.